1.
HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis
by McCaughan, Hugh
Journal of clinical pathology, 2012-07, Vol.65 (7), p.670-671
2.
Pertuzumab for the treatment of metastatic breast cancer
by Langdon, Simon P
Expert review of anticancer therapy, 2013-08-01, Vol.13 (8), p.907-918
3.
Endocrine therapy in epithelial ovarian cancer
by Langdon, Simon P
Expert review of anticancer therapy, 2017-02-01, Vol.17 (2), p.109-117
4.
Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo
by LANGDON, S. P
Cancer chemotherapy and pharmacology, 1998, Vol.42 (5), p.429-432
5.
The stereochemical course of amino acid activation by methionyl- and tyrosyl-tRNA synthetases
by Langdon, Simon P
Nature (London), 1979-09-27, Vol.281 (5729), p.320-321
6.
Chapter 12 Reactivity of the workshop monoclonal antibodies with 9 human ovarian adenocarcinoma cell lines
by Langdon, Simon P
Lung cancer (Amsterdam, Netherlands), 1988, Vol.4 (1), p.62-64
7.
An exploratory evaluation of the Ward and Hudson Offending Pathways model with sex offenders who have intellectual disability
by Langdon, Peter E
Journal of intellectual & developmental disability, 2007, Vol.32 (2), p.94-105
8.
Grain Size Effect on Deformation Twinning and De-Twinning in a Nanocrystalline Ni-Fe Alloy
by Wang, Yan Bo
Materials science forum, 2010-12-30, Vol.667-669, p.181-186
